Lydia Meder
Overview
Explore the profile of Lydia Meder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
927
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meder L, Orschel C, Otto C, Koker M, Bragelmann J, Ercanoglu M, et al.
JCI Insight
. 2024 May;
9(10).
PMID: 38775153
Small cell lung cancer (SCLC) is the most aggressive lung cancer entity with an extremely limited therapeutic outcome. Most patients are diagnosed at an extensive stage. However, the molecular mechanisms...
2.
Gewalt T, Diehl L, Meder L
Front Oncol
. 2024 Mar;
14:1373308.
PMID: 38444685
No abstract available.
3.
Malchers F, Nogova L, van Attekum M, Maas L, Bragelmann J, Bartenhagen C, et al.
J Clin Invest
. 2023 Aug;
133(21).
PMID: 37606995
The discovery of frequent 8p11-p12 amplifications in squamous cell lung cancer (SQLC) has fueled hopes that FGFR1, located inside this amplicon, might be a therapeutic target. In a clinical trial,...
4.
Gewalt T, Noh K, Meder L
Oncol Res
. 2023 Jun;
31(2):101-115.
PMID: 37304235
LIN28B is an RNA-binding protein that targets a broad range of microRNAs and modulates their maturation and activity. Under normal conditions, LIN28B is exclusively expressed in embryogenic stem cells, blocking...
5.
Hoppe S, Meder L, Gebauer F, Ullrich R, Zander T, Hillmer A, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230712
Introduction: The Trophoblast cell surface antigen 2 (TROP2) is expressed in many carcinomas and may represent a target for treatment. Sacituzumab govitecan (SG) is a TROP2-directed antibody-drug conjugate (ADC). Nearly...
6.
Borchmann S, Selenz C, Lohmann M, Ludwig H, Gassa A, Bragelmann J, et al.
J Immunother Cancer
. 2022 Oct;
10(10).
PMID: 36223955
Background: Single-agent immunotherapy has shown remarkable efficacy in selected cancer entities and individual patients. However, most patients fail to respond. This is likely due to diverse immunosuppressive mechanisms acting in...
7.
Yu X, Eischeid-Scholz H, Meder L, Kondylis V, Buttner R, Odenthal M
Hum Cell
. 2022 Sep;
35(6):1766-1784.
PMID: 36050615
MicroRNA dysregulation is a hallmark of hepatocellular carcinoma (HCC), leading to tumor growth and metastasis. Previous screening on patient specimens identified miR-198 as the most downregulated miRNA in HCC. Here,...
8.
Selenz C, Compes A, Nill M, Borchmann S, Odenthal M, Florin A, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36010935
EGFR-driven non-small-cell lung cancer (NSCLC) patients are currently treated with TKIs targeting EGFR, such as erlotinib or osimertinib. Despite a promising initial response to TKI treatment, most patients gain resistance...
9.
Bragelmann J, Lorenz C, Borchmann S, Nishii K, Wegner J, Meder L, et al.
Nat Commun
. 2021 Sep;
12(1):5505.
PMID: 34535668
Kinase inhibitors suppress the growth of oncogene driven cancer but also enforce the selection of treatment resistant cells that are thought to promote tumor relapse in patients. Here, we report...
10.
Meder L, Florin A, Ozretic L, Nill M, Koker M, Meemboor S, et al.
Pathol Oncol Res
. 2021 Jul;
27:596522.
PMID: 34257546
Abrogation of Notch signaling, which is pivotal for lung development and pulmonary epithelial cell fate decisions was shown to be involved in the aggressiveness and the differentiation of lung carcinomas....